Erlotinib — Dosing in CKD & Dialysis

Erlotinib (Tyrosine Kinase Inhibitor): renal dosing adjustments, dialyzability (Not meaningfully affected by hemodialysis: pharmacokinetics on a dialysis day were little different from a non-dialysis day in 3 patients (Togashi 2010, PMID 20234322).), and renal-relevant safety risk for CKD and dialys

Reviewed by Matt · November 16, 2026

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.